Tuberculosis has remained, unambiguously, a significant health care problem since long times, particularly in
developing countries. The endeavoring battle against multi drug resistant TB, multiple dosing, their prominent side effects
and bioavailability hiccups related to fixed dose combinations has undeniably become a Herculean task indicating rigorous
research requirement in anti TB drug therapy. In view of the fact that patenting a drug molecule, a drug delivery system
or a formulation has been very fruitful for the growth and sustainment of pharmaceutical industry, a meticulous review
of recent developments, providing a balanced view on merits/demerits, will facilitate researchers to update themselves,
thereby focusing their research in more relevant areas to furnish desired quality traits. This article reviews the present
scenario in terms of drug delivery approaches for TB chemotherapy. The review encompasses and summarizes recent
patents and advances on variegated facets of dosage forms, together with from conventional solid oral to novel controlled
release oral formulations and additionally alternative weapons for anti TB drug delivery. A critical review of multidisciplinary
approaches to boost anti TB therapy may facilitate the scientists to resolve existing technological gaps.
Keywords: Bioavailability, fixed dose combination, novel drug delivery, patents, stability, tuberculosis.
Rights & PermissionsPrintExport